Le et al., in a phase II trial, showed that patients with MMR-deficient metastatic colorectal cancer had significantly improved survival with pembrolizumab than those with MMR-intact tumours (HR of death 0.22, p = 0.05) [96]. Here, MRC1 is linked to neoplasm.